...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The journal of clinical psychiatry >Sexual satisfaction and quality of life in major depressive disorder before and after treatment with citalopram in the STAR*D study
【24h】

Sexual satisfaction and quality of life in major depressive disorder before and after treatment with citalopram in the STAR*D study

机译：STAR * D研究中西酞普兰治疗前后主要抑郁症的性满意度和生活质量

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective: Major depressive disorder (MDD) patients often experience impaired sexual satisfaction (ISS) and poor quality of life (QOL). Selective serotonin reuptake inhibitors (SSRIs), the first-line treatment for MDD, can cause sexual dysfunction, potentially worsening ISS and QOL. This study examined the impact of MDD and the SSRI citalopram on sexual satisfaction and QOL in level 1 of the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial (July 2001-September 2006). Method: A retrospective analysis was conducted of the change in sexual satisfaction, as measured by item 9 of the Quality of Life Enjoyment and Satisfaction Questionnaire, the primary outcome measure, in 2,280 patients with DSMIV- TR-defined MDD who were treated with citalopram for 12 weeks. The Quick Inventory of Depressive Symptomatology- Self Report was used to evaluate the impact of depression ratings on impaired sexual satisfaction and on QOL. Results: Impaired sexual satisfaction was present in 64.3% of MDD patients at pretreatment, but that percentage declined to 47.1% at posttreatment with citalopram (P .0001). Those who achieved remission had less ISS and better QOL. The prevalence of ISS in remitters was 21.2% versus 61.3% in nonremitters (P 10-8). The mean ± standard deviation score for remitters increased from 2.32 ± 1.16 to 3.44 ± 1.23 (P 10-8; Cohen d = 0.81 [large effect size]), whereas in nonremitters it increased only from 1.99 ± 1.08 to 2.19 ± 1.19 (P 10-8; Cohen d = 0.16). The difference between remitters and nonremitters was highly significant (P 10-8). Regression analyses at pretreatment and posttreatment demonstrated significant associations between depressive symptoms and ISS (P .0001) and between ISS and lower QOL (P .0001) as well as an association between citalopram and increased probability of ISS and a poorer QOL in patients who continue to have moderate-to-severe depression. Conclusions: A majority of MDD patients have impaired sexual satisfaction, a symptom associated with poor QOL. Despite the sexual side effects of the SSR citalopram, treating depression to full remission was associated with improvements in sexual satisfaction and QOL.
机译：目的：重度抑郁症（MDD）患者经常经历性满意度（ISS）受损和生活质量（QOL）下降。选择性5-羟色胺再摄取抑制剂（SSRIs）是MDD的一线治疗药物，可引起性功能障碍，可能使ISS和QOL恶化。这项研究在2001年7月至2006年9月进行的缓解抑郁症的序贯治疗替代方案（STAR * D）试验的第1级中，研究了MDD和SSRI西酞普兰对性满意度和QOL的影响。方法：对2,280例接受西酞普兰治疗的DSMIV-TR定义的MDD患者中的生活满意度和满意度调查问卷（第9项主要结果指标）第9条所测量的性满意度的变化进行了回顾性分析。 12周抑郁症状快速调查表-自我报告用于评估抑郁等级对性满意度和生活质量受损的影响。结果：接受治疗的64.3％的MDD患者的性满意度降低，但使用西酞普兰治疗后的这一比例下降至47.1％（P <.0001）。获得缓解的人的ISS更少，而QOL更好。 ISS患病者的患病率为21.2％，而非患病者的患病率为61.3％（P <10-8）。汇款者的平均±标准差评分从2.32±1.16增加到3.44±1.23（P <10-8; Cohen d = 0.81 [较大效应值]），而在非汇款者中，它仅从1.99±1.08增加到2.19±1.19（ P <10-8;科恩d = 0.16）。汇款人与非汇款人之间的差异非常显着（P <10-8）。治疗前和治疗后的回归分析表明，抑郁症状与ISS（P <.0001）之间以及ISS与较低QOL（P <.0001）之间存在显着相关性，西酞普兰与ISS发生率增加和患者QOL较差之间存在相关性他们继续患有中度至重度抑郁症。结论：大多数MDD患者的性满意度降低，这是QOL不良的症状。尽管SSR西酞普兰具有性副作用，但治疗抑郁症至完全缓解仍可改善性满意度和生活质量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号